BioCentury | Jan 6, 2014
Company News

Ocera, Genentech, Roche deal

...of the company's streamlining activities following its merger with the Terrapin Acquisition Inc. subsidiary of Tranzyme Inc....
BioCentury | Oct 28, 2013
Company News

Neos Therapeutics management update

...Business: Drug delivery, Neurology Hired: Vipin Garg as CEO and a director, formerly CEO of Tranzyme Inc....
BioCentury | Sep 30, 2013
Company News

Ocera hepatic news

...Ocera acquired the research facility through its merger with the Terrapin Acquisition Inc. subsidiary of Tranzyme Inc....
BioCentury | Jul 22, 2013
Company News

Ocera, Tranzyme deal

...San Diego, Calif. Tranzyme Inc. , Durham, N.C. Business: Hepatic Ocera completed its merger with Tranzyme's...
...stock deal to form Ocera Therapeutics Inc. (NASDAQ:OCRX, San Diego, Calif.). Prior to the merger, Tranzyme...
...split. Following the close, former Ocera shareholders own about 71% of the company and former Tranzyme...
BioCentury | Jul 22, 2013
Financial News

Ocera completes private placement

...the merger of privately owned Ocera Therapeutics Inc. with the Terrapin Acquisition Inc. subsidiary of Tranzyme Inc....
BioCentury | May 13, 2013
Company News

Ocera, Tranzyme deal

...Tranzyme and Ocera said that Ocera will merge with Tranzyme's Terrapin Acquisition Inc. subsidiary in a...
...Therapeutics Inc. After the merger, former Ocera shareholders will own 72.6% of the company and Tranzyme...
...approval in the EU to treat irritable bowel syndrome (IBS). In connection with the merger, Tranzyme...
BioCentury | May 13, 2013
Company News

Ocera, Tranzyme deal

...Tranzyme and Ocera said that Ocera will merge with Tranzyme's Terrapin Acquisition Inc. subsidiary in a...
...Therapeutics Inc. After the merger, former Ocera shareholders will own 72.6% of the company and Tranzyme...
...approval in the EU to treat irritable bowel syndrome (IBS). In connection with the merger, Tranzyme...
BioCentury | May 13, 2013
Company News

Ocera, Tranzyme deal

...Tranzyme and Ocera said that Ocera will merge with Tranzyme's Terrapin Acquisition Inc. subsidiary in a...
...Therapeutics Inc. After the merger, former Ocera shareholders will own 72.6% of the company and Tranzyme...
...approval in the EU to treat irritable bowel syndrome (IBS). In connection with the merger, Tranzyme...
BioCentury | Feb 18, 2013
Company News

Tranzyme gastrointestinal news

...symptoms of gastroparesis after a planned interim futility analysis showed insufficient efficacy. At the time, Tranzyme...
...details or next steps for the oral ghrelin agonist program (see BioCentury, Dec. 24, 2012). Tranzyme Inc....
BioCentury | Jan 21, 2013
Company News

Tranzyme management update

Tranzyme Inc. (NASDAQ:TZYM), Durham, N.C. Business: Gastrointestinal, Endocrine/Metabolic, Chemistry Promoted: David Moore to CBO from VP of commercial operations WIR Staff Gastrointestinal...
Items per page:
1 - 10 of 128
BioCentury | Jan 6, 2014
Company News

Ocera, Genentech, Roche deal

...of the company's streamlining activities following its merger with the Terrapin Acquisition Inc. subsidiary of Tranzyme Inc....
BioCentury | Oct 28, 2013
Company News

Neos Therapeutics management update

...Business: Drug delivery, Neurology Hired: Vipin Garg as CEO and a director, formerly CEO of Tranzyme Inc....
BioCentury | Sep 30, 2013
Company News

Ocera hepatic news

...Ocera acquired the research facility through its merger with the Terrapin Acquisition Inc. subsidiary of Tranzyme Inc....
BioCentury | Jul 22, 2013
Company News

Ocera, Tranzyme deal

...San Diego, Calif. Tranzyme Inc. , Durham, N.C. Business: Hepatic Ocera completed its merger with Tranzyme's...
...stock deal to form Ocera Therapeutics Inc. (NASDAQ:OCRX, San Diego, Calif.). Prior to the merger, Tranzyme...
...split. Following the close, former Ocera shareholders own about 71% of the company and former Tranzyme...
BioCentury | Jul 22, 2013
Financial News

Ocera completes private placement

...the merger of privately owned Ocera Therapeutics Inc. with the Terrapin Acquisition Inc. subsidiary of Tranzyme Inc....
BioCentury | May 13, 2013
Company News

Ocera, Tranzyme deal

...Tranzyme and Ocera said that Ocera will merge with Tranzyme's Terrapin Acquisition Inc. subsidiary in a...
...Therapeutics Inc. After the merger, former Ocera shareholders will own 72.6% of the company and Tranzyme...
...approval in the EU to treat irritable bowel syndrome (IBS). In connection with the merger, Tranzyme...
BioCentury | May 13, 2013
Company News

Ocera, Tranzyme deal

...Tranzyme and Ocera said that Ocera will merge with Tranzyme's Terrapin Acquisition Inc. subsidiary in a...
...Therapeutics Inc. After the merger, former Ocera shareholders will own 72.6% of the company and Tranzyme...
...approval in the EU to treat irritable bowel syndrome (IBS). In connection with the merger, Tranzyme...
BioCentury | May 13, 2013
Company News

Ocera, Tranzyme deal

...Tranzyme and Ocera said that Ocera will merge with Tranzyme's Terrapin Acquisition Inc. subsidiary in a...
...Therapeutics Inc. After the merger, former Ocera shareholders will own 72.6% of the company and Tranzyme...
...approval in the EU to treat irritable bowel syndrome (IBS). In connection with the merger, Tranzyme...
BioCentury | Feb 18, 2013
Company News

Tranzyme gastrointestinal news

...symptoms of gastroparesis after a planned interim futility analysis showed insufficient efficacy. At the time, Tranzyme...
...details or next steps for the oral ghrelin agonist program (see BioCentury, Dec. 24, 2012). Tranzyme Inc....
BioCentury | Jan 21, 2013
Company News

Tranzyme management update

Tranzyme Inc. (NASDAQ:TZYM), Durham, N.C. Business: Gastrointestinal, Endocrine/Metabolic, Chemistry Promoted: David Moore to CBO from VP of commercial operations WIR Staff Gastrointestinal...
Items per page:
1 - 10 of 128